Trials / Completed
CompletedNCT00668122
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections
Efficacy and Safety of Ciprofloxacin Extended-Release 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cipro XR (Ciprofloxacin, BAYQ3939) | Ciprofloxacin XR 1000 mg orally once a day |
| DRUG | Cipro IR (Ciprofloxacin, BAYQ3939) | Ciprofloxacin IR 500 mg orally twice a day |
Timeline
- Start date
- 2004-03-01
- Completion
- 2006-01-01
- First posted
- 2008-04-28
- Last updated
- 2009-06-30
Locations
38 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00668122. Inclusion in this directory is not an endorsement.